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Review Article
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Regarded as constitutively active enzymes, known to participate in many, diverse bio-
logical processes, the intracellular regulation bestowed on the CK1 family of serine/threo-
nine protein kinases is critically important, yet poorly understood. Here, we provide an
overview of the known CK1-dependent cellular functions and review the emerging roles
of CK1-regulating proteins in these processes. We go on to discuss the advances, limita-
tions and pitfalls that CK1 researchers encounter when attempting to define relationships
between CK1 isoforms and their substrates, and the challenges associated with ascer-
taining the correct physiological CK1 isoform for the substrate of interest. With increasing
interest in CK1 isoforms as therapeutic targets, methods of selectively inhibiting CK1
isoform-specific processes is warranted, yet challenging to achieve given their participa-
tion in such a vast plethora of signalling pathways. Here, we discuss how one might shut
down CK1-specific processes, without impacting other aspects of CK1 biology.
Introduction
The post-translational modification of proteins offers multiple and diverse ways of controlling protein
function. Of the post-translational modifications that proteins can undergo in cells, phosphorylation is
perhaps one of the best studied to date. Protein kinases, the enzymes that catalyse the phosphorylation
of primarily serine, threonine, and tyrosine residues on protein substrates [1,2], play fundamental
roles in controlling the plethora of signal transduction pathways, and therefore represent important
targets for therapeutic intervention [3–5]. By phosphorylating their protein substrates, kinases are able
to impart critical spatiotemporal regulation on various aspects of that substrate’s function, such as
promoting a change in its activity or stability, altering its binding to other effectors, or promoting a
change in its subcellular distribution [2]. Thus, protein kinases play essential roles within biological
systems.
In humans, the kinase superfamily has been classified into two principle groups, comprising the
eukaryotic protein kinases, of which there are 497, and the atypical protein kinases, of which there are
58 [6]. The eukaryotic protein kinases can be further segregated into several families based on
sequence similarities within their kinase domains [7]. A dendrogram encapsulating all human protein
kinases is commonly referred to as the kinome tree, where each specific branch represents a family of
similar kinases [7]. The serine/threonine (Ser/Thr) protein kinase CK1 family forms its own distinct
branch of the kinome tree [7] (Figure 1A), and constitutes one of the first Ser/Thr protein kinase fam-
ilies to be discovered [8]. The CK1 branch includes the CK1 isoforms, and the closely related
vaccinia-related kinases (VRKs) and tau tubulin kinase 1 (TTBK1) members [7,9]. Historically, CK1
and an unrelated protein belonging to the CMGC family of protein kinases named casein kinase 2
(CK2), were named for their ability to phosphorylate the milk protein casein in vitro [10]. However, it
should be noted that CK1 members are not the physiological casein kinases [10,11]. The bona fide
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casein kinase was recently identified as FAM20C, a Golgi-resident protein kinase that is capable of phosphoryl-
ating many secreted proteins, including casein [11–15]. Due to this misnomer, many studies use CK2 as a
control in experiments seeking to prove that the phosphorylation of the substrate of interest is specific to CK1,
whereas they are in fact unrelated enzymes.
Seven mammalian CK1 isoforms and their associated splice variants have been reported (Figure 1A). These
include the α, α-like, γ1, γ2, γ3, δ and ɛ CK1 isoforms, which have been grouped together based on their high
degree of homology within their N-terminal kinase domains (Figure 1B). Outside of the kinase domain, there
is little homology between CK1 members. Importantly, CK1 kinases are encoded by distinct genes, and are not
splice variants, although splice variants do exist for some CK1 isoforms [16]. For example, there are three tran-
script variants for human CK1δ [17], and two transcript variants for human CK1α [18]. Interestingly, zebrafish
present with four CK1α variants [19]. Within the CK1 family, the α, α-like, δ and ɛ isoforms share a higher
degree of sequence similarity in their kinase domains when compared with those of the γ isoforms [16,20,21].
To date, most investigations have focussed on the CK1α, δ and ɛ isoforms, whilst the functions and regulation
of the α-like and CK1γ isoforms have remained somewhat elusive, although mounting evidence supports roles
for CK1γ in the regulation of immune signalling pathways [22,23]. As such, the major focus of this review will
concern CK1α, δ and ɛ.
All CK1 isoforms have been reported to act as monomeric enzymes and are classically thought to exist in a
constitutively active state [16,20,21]. However, studies demonstrating constitutive activity of CK1 isoforms have
largely been performed in vitro with purified catalytic domains, and as such fail to capture any potential regula-
tion from accessory proteins or other enzymes. It is now becoming clear that certain CK1 isoforms can become
activated through direct association with cellular proteins [24]. A comprehensive comparison between the
enzyme kinetics of each CK1 isoform, and any associated splice variants, is lacking, but the basal activities are
likely different for each isoform, and most likely depend on the substrate used. CK1 family members catalyse
the transfer of phosphate on to Ser/Thr residues of their protein substrates by utilising ATP exclusively as the
source of the phosphate donor [25,26]. That said, the yeast orthologue of CK1δ, Hrr25, has been reported to
phosphorylate tyrosine (Tyr) residues in addition to Ser/Thr [27], and the Xenopus laevis orthologue of CK1α
was shown to phosphorylate Tyr residue in synthetic peptide substrates [28]. As ubiquitously expressed kinases,
CK1 isoforms have been reported to be involved in numerous, seemingly unrelated signalling pathways, and
many proteins have been reported to be phosphorylated by CK1 isoforms [16,20,21,29]. In terms of conserva-
tion, the CK1 family are conserved throughout evolution, and several CK1 orthologues have been identified in
other vertebrates, as well as yeast, plants, and protozoa [19,30–35].
Early attempts aimed at elucidating the substrate specificity of CK1 identified the requirement for a priming
phosphorylation event in the -3 position of the CK1 phosphorylation site. This consensus sequence of pS/
pT-X-X-S*/T*, where X is any amino acid and S*/T* denotes CK1-phosphorylation residues, has long since
been suggested as the optimal CK1 phosphorylation motif [25,36,37]. Given this requirement for a priming
Figure 1. Domain architecture of CK1 isoforms.
(A) Phylogenetic tree of the CK1 family of protein kinases (based on [7]). (B) Schematic detailing the domain architecture for the
CK1 isoforms. Percentage sequence similarity of the kinase domains for each CK1 isoform, relative to the CK1α kinase
domain, is shown.
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).4604
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phosphorylation event, CK1 isoforms were thought to act downstream of other kinases, and as such, this
restricted their contribution within signalling cascades to one of a hierarchical manner, with CK1 isoforms
phosphorylating substrates only when the substrate had been pre-phosphorylated by another priming kinase.
However, it has since come to light that a cluster of acidic residues N-terminal to the target Ser/Thr phosphor-
ylation sites, with an acidic amino acid at the −3 position, can effectively substitute for the priming phosphor-
ylation event [38–42]. Furthermore, a non-canonical S-L-S motif with a concurrent cluster of C-terminal acidic
residues has also been shown to be phosphorylated by CK1 isoforms, albeit less efficiently than the canonical
phospho-primed sequence [16,43]. Such phosphorylation of S-L-S motifs is best showcased in two of the most
robustly established CK1 substrates — nuclear factor of activated T-cells (NFAT) and β-catenin [16,43].
Intriguingly, a novel CK1 phosphorylation motif, K/R-X-K/R-X-X-S/T, was reported to be phosphorylated in
several sulfatides and cholesterol-3-sulfate binding proteins [44]. These observations imply that CK1 isoforms
can phosphorylate Ser/Thr residues that are not defined by a specific sequence motif, suggesting that the phos-
phorylation of specific substrates in cells is likely to be regulated by other factors, such as determinants of their
subcellular distribution and substrate recruitment.
Regulation of CK1 in cells
Most CK1 isoforms are ubiquitously expressed across many tissues and cell lines. However, studies on the
expression levels of CK1δ and ɛ in young, healthy mice suggest that CK1 expression is regulated, and different
isoforms are expressed to different levels in distinct tissues [45–47]. The kinase domains, both sequence-wise
and structurally, are very similar between all CK1 isoforms (Figure 1B). Every CK1 isoform is constitutively
active in vitro, and each can phosphorylate substrate residues with identical motifs [16,20,21]. Due to most cel-
lular proteins harbouring at least one of the CK1 consensus motifs described above, it is not surprising that
hundreds of CK1 substrates have been reported thus far. However, the absence of isoform-selective CK1 inhibi-
tors has led to confusion regarding exactly which CK1 isoform is the physiological kinase for each of the identi-
fied substrates. However, recent years have seen some progress being made towards the generation of CK1
isoform-specific inhibitors (recently and thoroughly reviewed in [17]). Added complexity arises when consider-
ing the cellular environment. Indeed, the substrate specificity of CK1 isoforms in vitro is thought to be largely
different from that observed in vivo, and different isoforms are known to impact distinct biological processes,
suggesting tight regulation of distinct isoforms in cells [16,20,21]. This difference in the in vitro versus in vivo
substrate specificity is attributed to intracellular regulatory mechanisms involved in modulating CK1 isoforms,
including functional binding partners and post-translational modifications. Furthermore, as the kinase domain
of CK1 isoforms constitutes the vast majority of the protein sequence (Figure 1B), regulatory domains within
the protein sequence that are prevalent in many other kinases are very small within CK1 isoforms. Outside of
the kinase domains, the non-catalytic C-termini of CK1 isoforms vary substantially and are not conserved
between isoforms (Figure 1B). Nonetheless, the C-termini have been shown to play crucial roles in regulating
substrate recognition, and in the modulation of kinase activity for some CK1 isoforms [48,49]. With relatively
small C-termini, CK1 kinases may therefore require functional interacting partners, or regulatory subunits, for
their cellular regulation. These attributes have prompted researchers to ascertain the precise molecular mechan-
isms by which the activities of specific CK1 isoforms towards their cellular substrates are governed.
One prominent mode of regulation known to modulate CK1 function in cells involves the use of scaffold or
anchoring proteins, which function to direct and/or co-ordinate the correct positioning of protein complexes.
Scaffolds can also act as signalosome assembly platforms, bringing functional enzymes, such as kinases, in close
proximity to their substrate proteins, thereby increasing reaction efficiency through spatial control [50]. In
some cases, scaffold proteins have also been shown to allosterically activate their catalytic binding partners
[50,51]. In regard to the CK1 family of kinases, such scaffolds could be envisaged to regulate the constitutively
active CK1 members through multiple avenues. For example, scaffolds could bind and sequester CK1 isoforms
at discrete subcellular locations, either to take CK1 isoforms towards or away from their substrates, or act as
either a physical bridge or barrier between CK1 isoforms and their substrates. Furthermore, CK1 scaffolds may
act to promote or inhibit optimal CK1 activation through direct allosteric binding. Indeed, several protein scaf-
folds have been found to exert regulation towards some of the CK1 family members. For example, the centroso-
mal and Golgi N-kinase anchoring protein (CG-NAP, aka AKAP450) was shown to interact with CK1δ and ɛ
and recruit them to centrosomes [52] (Figure 2A). Furthermore, the DEAD-box RNA helicase DDX3 has been
shown to directly interact with CK1ɛ in a Wnt-dependent manner, to promote the phosphorylation of the Wnt
receptor-associated protein Dishevelled (Dvl) [24] (Figure 2B). In this case, DDX3 is suggested to be a direct
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 4605
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allosteric activator of CK1ɛ [24,53,54]. The Wnt signalling scaffold protein Axin, onto which the core compo-
nents of the β-catenin destruction complex assembles, has also been suggested to act as a CK1 anchoring
protein [55]. In this context, Axin is proposed to bind and sequester CK1ɛ away from Dvl, to limit
CK1ɛ-dependent phosphorylation of Dvl [55] (Figure 2B).
More recently, the Family of sequence similarity 83 (FAM83) family of proteins have been shown to interact
and co-localise with unique sets of CK1α, δ and ɛ isoforms, and in doing so, act to localise the interacting CK1
isoforms to distinct subcellular compartments to streamline CK1-dependent signalling [56,57] (Figure 2C). For
example, FAM83D was shown to direct CK1α to the mitotic spindle for proper spindle positioning [58], while
FAM83F directed CK1α to the plasma membrane to mediate Wnt signalling [59]. There are eight FAM83
members in vertebrates, designated FAM83A-H. Each FAM83 protein possesses an N-terminal domain of
unknown function 1669 (DUF1669), whilst the C-termini are unique and vary in both length and sequence
composition [56,57]. The key to establishing the streamlining roles of FAM83 proteins in CK1 biology has
been the identification of point mutations within the conserved DUF1669 domain, which abolish CK1 binding
and as a consequence inhibit specific functions of CK1 isoforms [56–60]. Interestingly, in the case of some
CK1 substrates, such as NFAT and the circadian clock protein Period 1 (PER1), an F-X-X-X-F motif on the
substrate was found to mediate the interaction with CK1 [61]. Whether this interaction mechanism is univer-
sally applicable for every CK1-binding partner remains to be determined, but for FAM83 proteins, which also
possess at least one F-X-X-X-F motif within their conserved DUF1669 domains, mutating the first phenylalan-
ine to alanine appears to abolish CK1 binding [56–58,60]. Intriguingly, the DUF1669 of FAM83 proteins har-
bours a short stretch of amino acids that resembles the catalytic motif of phospholipase D (PLD) enzymes, and
structural studies have shown similar architecture between the DUF1669 and PLDs [56,57]. The conventional
catalytic motif of PLD enzymes comprises the conserved consensus sequence H-X-K-X-X-X-X-D/E, where X is
any amino acid [62,63]. However, all FAM83 proteins, except FAM83D, lack the catalytic histidine, and no
PLD activity has been demonstrated for any of the FAM83 proteins to date [57]. Consequently, FAM83 pro-
teins are considered pseudophospholipases [57]. Curiously, mutation of the conserved aspartate residue within
the pseudo H-X-K-X-X-X-X-D/E motif of FAM83 proteins was also shown to disrupt the FAM83–CK1 inter-
action [56]. Furthermore, two additional FAM83G pathogenic palmoplantar keratoderma mutations, which
encode A34E and R52P substitutions within the conserved DUF1669 domain respectively, both led to the
inhibition of CK1 binding, suggesting that the interaction between the DUF1669 domain of FAM83 proteins
and CK1 appears to be more complicated than a simple binding motif [64]. As such, the molecular basis for
Figure 2. Reported regulators of CK1.
(A) CG-NAP localises CK1δ and ɛ to centrosomes. (B) CK1ɛ is sequestered and bound by Axin, which competes with Dvl for
CK1ɛ binding. Following Wnt stimulation, CK1ɛ dissociates from Axin and binds to DDX3. DDX3 increases the catalytic activity
of CK1ɛ to facilitate the phosphorylation of Dvl by CK1ɛ. (C) The FAM83 family of proteins co-ordinate the localisation of
distinct subsets of CK1 isoforms to various subcellular sites as shown. A question mark (?) denotes cases where the
physiological function of the FAM83–CK1 interaction is still to be determined.
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).4606
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the FAM83–CK1 interaction remains unresolved, and structural insights are required to fully understand the
interaction interface, and why these mutations disrupt the interaction.
Additionally, post-translational modifications of CK1 isoforms are known to be involved in the regulation of
CK1 activity. These are largely thought to occur through phosphorylation, either by CK1 itself through autop-
hosphorylation, or by other kinases [48,65,66]. In both cases, phosphorylation of CK1 was shown to be inhibi-
tory towards its intrinsic catalytic activity (for a comprehensive review on the phosphorylation of CK1
isoforms, see [17,67]). How then the CK1 family of kinases retain their reported constitutive activity remains
unclear, although phosphatase involvement has been inferred [68]. In the case of CK1 autophosphorylation,
CK1δ and ɛ have been proposed to autophosphorylate themselves on their C-terminal domains, with the result-
ing phosphopeptide acting as a pseudo-substrate, blocking the catalytic cleft of the kinase [49,68,69]. Curiously,
NEDDylation of CK1α was shown to modulate CK1 activity as well [70], although the exact relevance of this
NEDDylation event remains to be defined.
The many roles of CK1 in biology
Given the reported phosphorylation of numerous substrates by CK1 family isoforms, it is perhaps unsurprising
that CK1 kinases have been implicated in a plethora of biological processes [16,20,21]. The most studied of
these biological processes will each be reviewed in the sections that follow.
CK1 isoforms control many components of Wnt signalling
To date, the canonical Wnt signalling pathway is perhaps the best characterised CK1-regulated process in cells
(Figure 3). In short, stimulation of the cognate Wnt receptors through Wnt ligands leads to the nuclear trans-
location of the transcription factor β-catenin, ultimately resulting in transcription of Wnt-dependent target
genes [71]. In the absence of Wnt ligands, β-catenin is sequestered by the so-called β-catenin destruction
complex, which consists of the scaffold proteins Axin and Adenomatous Polyposis Coli (APC), the
SKP1-Cul1-F-Box protein E3 ubiquitin ligase (SCF) substrate receptor β-TrCP, and the kinases Glycogen
Synthase Kinase 3 (GSK3) and CK1 [71,72] (Figure 3). Within this destruction complex, the current model
proposes that β-catenin is first phosphorylated by CK1 on Ser45, thereby priming β-catenin for subsequent,
sequential phosphorylation on Thr41, Ser37 and Ser33 by GSK3 [43,73–76]. Next, this phosphorylated β-catenin
species is ubiquitinated by the β-TrCP-SCF complex, priming it for degradation via the proteasome [53]. In the
presence of Wnt ligands, however, Axin is expelled from the destruction complex through as yet unidentified
mechanisms, and phosphorylated β-catenin is thought to accumulate and saturate the destruction complex
[53,72,77]. Subsequently, the newly translated β-catenin is free to translocate to the nucleus and mediate tran-
scription of Wnt target genes [53,72,77].
Despite this seemingly resolved model, the exact CK1 isoform that mediates phosphorylation of β-catenin on
Ser45 has not been irrefutably identified. This is largely due to the non-selective nature of CK1 inhibitors, and
the fact that CK1 isoforms are largely essential for cell viability, thereby making genetic ablation experiments
very challenging, if not impossible. Indeed, virtually all CK1 isoforms have been implicated in Wnt signalling
[53,78,79], making it extremely difficult to decipher the function of individual CK1 members within the Wnt
pathway. Further complexity in the regulation of Wnt signalling by CK1 isoforms stems from the reported
phosphorylation of the Wnt receptor-associated protein Dvl by CK1ɛ, which is thought to increase the affinity
between Dvl and the Wnt receptor complex [29,55,78,80]. Thus, in this context, CK1-mediated phosphoryl-
ation acts to promote Wnt signalling, in stark contrast with its inhibitory role within the destruction complex.
Interestingly, a recent study proposed a model whereby Axin1 competes with Dvl for CK1ɛ binding to limit
the phosphorylation of Dvl by CK1ɛ and block the activation of Wnt signalling [55]. Thus, exactly how CK1
isoforms can act to both positively and negatively regulate the same signalling pathway presents an intriguing
paradox, yet adds further credence to the critical role that cellular CK1 regulators must play in order to
co-ordinate the spatiotemporal activity of these constitutively active protein kinases. Consistent with this
notion, FAM83G [also known as Protein Associated with SMAD1 (PAWS1)] was recently shown to
promote Wnt signalling in both human cancer cells and in Xenopus embryos, through direct association with
CK1α [60]. Knockout of FAM83G severely impeded canonical Wnt signalling, and its overexpression in
Xenopus presented with axis duplication phenotypes [60]. FAM83G, which primarily localises to the cytosol,
appears to regulate the nuclear translocation of β-catenin, although the precise molecular mechanisms by
which this is achieved remain unresolved [60]. As described above, it was recently shown that two pathogenic
mutants of FAM83G, leading to A34E and R52P substitutions respectively, known to cause palmoplantar
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 4607
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keratoderma, failed to both associate with CK1α and activate Wnt signalling [64]. Intriguingly, ablation of
CK1α from murine skin keratinocytes resulted in epidermal hyperpigmentation in the footpads, resembling
phenotypes observed in the palms and soles of human patients with palmoplantar keratoderma resulting from
FAM83G mutations [64,81,82]. More recently, FAM83F was also shown to mediate Wnt signalling through its
association with CK1α, although in this case the regulation occurred at the plasma membrane and upstream of
the β-catenin destruction complex [59]. Thus, in the case of CK1α, two distinct FAM83 proteins have now
been shown to regulate where CK1α acts within the Wnt pathway, suggesting that at least some of the seem-
ingly antagonistic roles of CK1 isoforms within the Wnt signalling cascade can be explained by spatiotemporal
control imparted by functional binding partners.
CK1 isoforms modulate p53 signalling
The tumour suppressor protein p53 functions as a key regulator of many aspects of biology, including the cell
cycle, apoptosis and DNA damage responses [83]. p53 and its inhibitory interacting proteins Mouse Double
Minute Homologue 2 and 4 (MDM2 and MDM4) are all reported as substrates of CK1 isoforms [84–86].
MDM2 and MDM4 are E3 ubiquitin ligases responsible for regulating p53 stability. CK1α, δ and ɛ are all
Figure 3. CK1 in Wnt signalling.
In the absence of Wnt ligands, β-catenin is held by the so-called destruction complex composed of Axin, APC, the E3 ubiquitin
ligase substrate receptor β-TrCP, and the kinases CK1 and GSK3. Sequential phosphorylation of β-catenin by CK1 and GSK3
triggers β-catenin ubiquitination by the β-TrCP-complex, and its subsequent proteasomal degradation. In the nucleus, Groucho
binds TCF to block the transcription of Wnt target genes. Following binding of Wnt ligands to the receptors LRP5/6 and FZD,
LRP5/6 becomes phosphorylated, and triggers the formation of the Wnt signalosome, largely composed of Axin and Dvl. This
recruits the destruction complex to the membrane. β-catenin is stabilised in the cytosol and is free to enter the nucleus where
it displaces Groucho from TCF, and together with LEF, activates transcription of Wnt target genes. CK1 has also been reported
to phosphorylate the LRP5/6 and Dvl in the presence of Wnt ligands.
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).4608
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capable of phosphorylating p53 at Ser9 in vitro, with phosphorylation by CK1α only occurring at high CK1α
concentrations [87]. Phosphorylation of Ser9 is thought to result in p53 activation [88]. Additionally, CK1δ
and ɛ were shown to phosphorylate p53 in cultured cells [85]. CK1δ-mediated phosphorylation of MDM2 was
shown to result in reduced affinity between p53 and MDM2, thereby resulting in stabilisation and subsequent
activation of p53 [84–86]. Thus, the data would suggest that CK1 activity is important in p53 activation.
However, and as seen in Wnt signalling, different CK1 isoforms can have contrasting effects on p53 signal-
ling, depending on the experimental conditions used and the cell type being investigated. For example, in con-
trast with the stimulatory effects of p53 phosphorylation by CK1 δ and ɛ, knockdown of CK1α has been shown
to activate p53 [89–91], suggesting CK1α can inhibit p53 activation, either directly or indirectly. In agreement,
one study showed that CK1α associates with MDM2 to inactivate p53, through increasing MDM2–p53 binding
affinity [92]. This was further cemented through independent observations where CK1α knockdown led to a
reduction in the MDM2–p53 interaction, thereby increasing p53 activity [93]. Interestingly, a recent publication
reported that ablation of CK1α in keratinocytes induced p53-dependent, sunburn-protective skin hyperpigmen-
tation, in further agreement with CK1α regulating p53 stability [81]. Curiously, p53 activation was associated
with up-regulation of CK1δ, but not CK1ɛ, thereby suggesting an autoregulatory feedback mechanism between
CK1δ and p53 [85]. Indeed, CK1δ kinase activity is reduced in p53-deficient primary lymphocytes, compared
with wild-type controls [46]. Thus, at least in the case of CK1δ in p53 signalling, the role of CK1 phosphoryl-
ation appears to be more complex than a mere kinase-substrate relationship. It was recently reported that
FAM83F was involved in mediating p53 stabilisation and activity during DNA damage [94], but this study did
not assess whether these effects of FAM83F relied on its ability to bind to CK1α.
CK1 isoforms dampen down Hippo signalling
During development, Hippo signalling contributes to correct organ maturation through regulation of cell prolif-
eration and apoptosis [95]. As such, dysfunctional Hippo signalling can lead to tumorigenesis and cancer. In
mammals, the Hippo pathway begins through stimulation by growth-suppressive signals, such as cellular stres-
ses and contact inhibition. Within the Hippo pathway, the upstream kinases Mammalian STE20-like protein
kinase 1/2 (MST1/2) act to phosphorylate the Large Tumour Suppressor 1 and 2 (LATS1/2), and LATS1/2 sub-
sequently phosphorylate the transcriptional co-activator Yes-associated Protein (YAP) and its paralog
Transcriptional Co-activator with PDZ-binding Domain (TAZ) [95] (Figure 4). YAP/TAZ phosphorylation
leads to their inhibition through phosphodegron-mediated proteolysis, in addition to promoting their separ-
ation from their cognate nuclear-localised transcription factor targets, such as SMADs [95] (Figure 4).
Effectively, YAP/TAZ phosphorylation leads to Hippo pathway inhibition.
CK1 isoforms have been suggested to regulate Hippo signalling (Figure 4). Indeed, both CK1δ and ɛ have
been proposed to phosphorylate YAP after priming phosphorylation from LATS1/2 [95]. This phosphorylation
was proposed to act as a phosphodegron signal, and mediate recruitment of the SCF E3 ubiquitin ligase
complex containing β-TrCP [95]. Similarly, CK1ɛ has been reported to phosphorylate TAZ to promote TAZ
degradation through a phosphodegron signal, again following priming phosphorylation from LATS1/2 [96].
Interestingly, cross-talk between the Wnt and Hippo pathways has been suggested to be mediated through
CK1ɛ [97]. Following MST1 binding to CK1ɛ, CK1ɛ is sequestered and unable to phosphorylate Dvl, thereby
leading to inhibition of the Wnt signalling pathway [97] (Figure 4). Thus, in this context, MST1 can act as a
key regulator of CK1ɛ, by promoting a change in its subcellular localisation and restricting access between
CK1ɛ and its substrates.
CK1 isoforms phosphorylate GLI and SMO to modulate
Hedgehog signalling
Hedgehog (Hh) signalling is critical for both correct development, and maintenance of healthy adult cells,
although the activity of the Hh signalling pathway is vastly reduced in adulthood [98]. Hh signalling contri-
butes to the maintenance of epithelia and tissue regeneration and, consequently, aberrant Hh signalling can
lead to tumorigenesis and cancer [99,100]. Within the mammalian Hh pathway, ligands such as Sonic
Hedgehog (Shh) bind to the negative regulator of the pathway, the transmembrane receptor Protein Patch
Homologue (PTCH), which exists in a complex with the positive Hh regulator Smoothened Homologue
Precursor (SMO) [101]. Upon PTCH stimulation, SMO is released from PTCH, and is free to mediate activa-
tion and release of GLI transcription factors from a cilia-localised GLI-inhibitory multiprotein complex
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containing the kinases CK1, GSK3 and Protein Kinase A (PKA) [101] (Figure 5). Once free, the GLI transcrip-
tion factors are free to translocate to the nucleus and induce transcription of Hh-dependent target genes.
Conversely, in the absence of PTCH stimulation by Hh ligands, SMO remains bound to PTCH, and the GLI
transcription factors are phosphorylated by CK1, GSK3 and PKA to trigger their proteasomal degradation
[101–103] (Figure 5).
In addition to the role of CK1 in promoting GLI transcription factor proteolysis, CK1 was also shown to
have a positive regulatory role on the Hh pathway. Mammalian SMO was shown to be phosphorylated by
CK1α and G Protein-coupled Receptor Kinase 2 (GRK2), to promote full SMO activation and release of GLI
transcription factors from the inhibitory multiprotein complex [104] (Figure 5). Thus, as seen with the other
signalling pathways reviewed above, CK1 isoforms appear to have both a positive and negative regulatory influ-
ence on the Hh signalling pathway, and understanding how these are regulated is critical for dissecting the
roles of individual CK1 isoforms.
CK1 isoforms at the heart of cell division
The cell cycle in eukaryotes is divided into two main phases: interphase, in which the cell replicates its
DNA in preparation for division; and M phase, in which the duplicated DNA is segregated and cell div-
ision takes places, creating two genetically identical daughter cells in the process [105]. Throughout the
Figure 4. CK1 in Hippo signalling.
Under conditions of low cell density, the YAP/TAZ transcriptional co-activator complex cycles between the cytosol and
nucleus, and in the nucleus YAP/TAZ bind to their cognate transcription factor targets, such as SMADs to trigger transcription
of Hippo target genes to promote cell growth and differentiation. CK1 phosphorylates Dvl to promote Wnt signalling under
these conditions. Under conditions of cell stress, such as contact inhibition, the kinase MST1/2 becomes activated and
phosphorylates LATS1/2, which promotes LATS1/2-mediated phosphorylation of YAP/TAZ. YAP/TAZ phosphorylation acts as a
phosphodegron signal to promote YAP/TAZ ubiquitination by β-TrCP, and subsequent YAP/TAZ proteolysis. As YAP/TAZ
cannot enter the nucleus, Hippo target gene transcription is suppressed, and cells cease to grow. CK1 has been reported to
phosphorylate YAP/TAZ after priming phosphorylation from LATS1/2, and following CK1 binding to MST1/2, CK1
phosphorylation of Dvl is reduced, leading to inhibition of Wnt signalling.
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cell division cycle, checkpoint mechanisms are in place to ensure the correct and efficient replication and
distribution of both the DNA, and the cytoplasm [105,106]. The yeast orthologue of CK1δ, Hrr25, was
among the first kinases identified to have a role in the regulation of cell cycle progression [107]. In
mammals, however, where there are multiple CK1 isoforms present, the precise contribution of each
isoform to the regulation of the cell division cycle is not well understood. CK1δ has been found to localise
to centrosomes, and displays a high affinity towards microtubules in response to DNA damage, suggesting
a checkpoint role for CK1δ in cell division [108,109]. Furthermore, inhibition of CK1δ/ɛ using IC261 is
accompanied with cell cycle arrest [108].
In addition to CK1δ, CK1α has long been suggested to have a role in mitosis. Early immunostaining efforts
identified CK1α on mitotic spindles [110], and injection of CK1α morpholinos triggered mitotic arrest and
chromosomal alignment defects in mouse oocytes [111]. Recently, the CK1α-specific binding protein FAM83D
was shown to be crucial for localising CK1α to mitotic spindles. Cells devoid of FAM83D, or those harbouring
a CK1-binding deficient F283A knockin mutation generated with CRISPR/Cas9 gene editing, failed to recruit
CK1α to the spindle apparatus [58]. Concomitantly, cells presented with spindle misorientation phenotypes,
and had a delayed metaphase-to-anaphase transition [58]. Furthermore, CK1α catalytic activity was demon-
strated to regulate the process of spindle positioning, which is critical in both development and for mainten-
ance of healthy adult tissues, in a manner dependent on its delivery to the spindle by FAM83D [58]. This
approach of targeting FAM83D had the added benefit of impacting only one CK1α-specific process, whilst
seemingly not affecting other aspects of CK1α biology. Thus, elucidating the involvement of CK1α in mitosis
was not hampered by any non-mitotic defects that would have resulted from pan-cellular knockdown or inhib-
ition of CK1α. Interestingly, a recent phosphoproteomic study reported that roughly 50% of all cell
cycle-regulated phosphopeptides conform to the predicted CK1 consensus substrate motifs [112], suggesting a
potentially profound role for CK1α in phosphorylating many substrates during mitosis.
Figure 5. CK1 in hedgehog signalling.
In the absence of hedgehog (Hh) ligands, the Hh receptor PTCH associates with SMO to inhibit SMO function. The GLI2/3
transcription factors are held in complex by a primary cilium-localized inhibitory complex consisting of the kinases CK1, GSK3
and PKA. Following GLI2/3 phosphorylation by CK1, GSK3 and PKA, GLI2/3 is marked for proteasomal degradation. In the
presence of Hh ligands, SMO is released from PTCH and is free to mediate the release of GLI2/3 from the inhibitory kinase
complex. GLI2/3 can now translocate to the nucleus and induce Hh target gene transcription. CK1 and GRK2 have been
reported to phosphorylate SMO to promote full SMO activation and maximal release of GLI2/3 from the inhibitory complex.
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CK1δ and ɛ as circadian rhythm switches
Circadian rhythms are biological processes that oscillate in a predictable, entrainable manner, and are regulated
by an endogenous time keeper, or circadian clock [113]. CK1 was the first kinase found to regulate the circa-
dian clock. In Drosophila, the CK1 orthologue Doubletime (dbt) phosphorylates the transcription factor Period
(PER), which acts to modulate the oscillatory circadian cycle [114]. In mammals, within the brain and periph-
ery, oscillatory transcriptional feedback encompasses the positive regulatory CLOCK–BMAL (Brain and muscle
ARNT-like) complex, which acts to activate transcription of the mammalian PER orthologues PER1-3, as well
as the Cryptochrome proteins CRY1-2 [115,116]. Following their transcription, the newly synthesised PER and
CRY proteins dimerise and translocate to the nucleus where they bind and inhibit the CLOCK–BMAL
complex, thereby preventing their own transcription [115,116]. In doing so, one circadian cycle is thus com-
pleted (Figure 6). Subsequently, CK1-dependent phosphorylation of PER proteins induces PER degradation by
the proteasome, thereby initiating a new circadian cycle, and the process repeats [117–119] (Figure 6). This
model, largely based on cell line research, was recently validated in vivo by introducing a PER2 S478A knockin
mutation into mice. CK1-dependent phosphorylation of Ser478 on PER2 triggers its association with β-TrCP,
leading to PER2 proteolysis. By mutating Ser478 to alanine, these knockin mice presented with longer circadian
rhythms and accumulated PER1 and CRY1/2 proteins in the nucleus, likely as a consequence of increased
PER2 stability [120]. CK1ɛ has also been shown to phosphorylate BMAL and CRY proteins [121], although the
relevance of these phosphorylation events are yet to be determined.
Figure 6. CK1 in circadian rhythm.
The circadian cycle begins with the CLOCK–BMAL complex, which acts to activate the transcription of PER and CRY proteins.
Following their translation, PER and CRY proteins heterodimerize and translocate to the nucleus, where they act to inhibit
CLOCK–BMAL, thereby preventing their own transcription. Subsequently, CK1 phosphorylates PER to trigger PER proteolysis
and relieve the CLOCK–BMAL inhibition. The cycle then begins again. CK1 has also been reported to phosphorylate CRY and
BMAL, but the relevance of these phosphorylation events remains to be elucidated.
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The exact physiological CK1 isoform(s) responsible for PER1/2 phosphorylation is a subject of debate, but
CK1δ and ɛ have both been implicated, and the vast majority of data support roles for both isoforms in the
regulation of circadian rhythm. Perhaps the most striking evidence for the involvement of CK1ɛ in the regula-
tion of circadian rhythm stems from evidence gathered in CSNK1E-deficient mice [122]. In these mice, which
lack expression of CK1ɛ, the length of circadian rhythms were significantly longer compared with wild-type lit-
termates [122]. Furthermore, a mutation in the Syrian hamster CSNK1E1 gene, encoding a CK1ɛ protein with
a T178C substitution, increases catalytic activity towards PER proteins, resulting in reduced PER stability and
shorter circadian rhythms [123]. However, mice heterozygous for CSNK1D deletion also presented with longer
circadian rhythms, whereas homozygous CSNK1D knockout mice died in the perinatal period [122].
Collectively, there is strong evidence supporting roles for both CK1δ and ɛ in circadian rhythm regulation,
suggesting that there may be redundancy between these two enzymes. As CK1δ and ɛ are very closely related
proteins, it is feasible that they may act redundantly in some contexts. The fact that CSNK1E-deficient mice are
viable, whereas CSNK1D-deficient mice are not [122], perhaps suggests that the non-circadian rhythm func-
tions of CK1δ are indispensable for viability, whereas those of CK1ɛ appear to be dispensable. Thus, there
seems to be a limit to CK1δ and ɛ redundancy at least in some contexts, likely dependent on the biological
process in question.
CK1 appears to inhibit programmed cell death
Programmed cell death, or apoptosis, is an evolutionarily conserved mechanism whereby cells act to terminate
themselves in an effort to limit the proliferation of faulty and disease-prone cell populations [124]. In
short, proteins called death receptors such as Fas, and Tumour Necrosis Factor Receptor 1 (TNFR1), act
to transduce extrinsic apoptotic cues, ultimately leading to the formation of the intracellular
Death-inducing-signalling-complex (DISC) [124]. DISC proteins go on to recruit caspases in order to propagate
the apoptotic signal [124]. The involvement of CK1 in apoptosis has been well documented, and CK1 has been
implicated in various programmed cell death molecular pathways. CK1 isoforms can phosphorylate the TNF
receptor p75, thereby negatively regulating p75-mediated apoptosis [125]. Furthermore, inhibition of CK1 iso-
forms, or RNAi-mediated silencing of CSNK1A1, sensitises tumour cells to TNF-related Apoptosis-inducing
Ligand (TRAIL)-induced apoptosis [126]. Recently, IC261-mediated inhibition of CK1δ/ɛ was shown to result
in decreased expression of anti-apoptotic proteins, with a concurrent heightened sensitivity to apoptosis, in
pancreatic cancer cells [127]. Furthermore, CK1 has been reported to phosphorylate receptor-interacting
protein kinase 3 (RIPK3) on Ser227 to activate necroptosis — a form of immunogenic cell death [128]. In this
study, the authors reported that CK1α, δ and ɛ all associate with RIPK3 upon induction of necroptosis in HeLa
cells, and showed an increase in cell viability when CK1 isoforms were knocked out in this cell line [128].
However, given the plethora of signalling pathways CK1 isoforms are implicated in, whether this increase in
cell survival is a direct result of inhibited necroptosis requires further study. Curiously, CK1γ1 and γ3 have also
been reported to phosphorylate RIPK3 to stimulate necroptosis [23], whilst recent data suggests CK1γ2 phos-
phorylates and inhibits RIPK3 to suppress necroptosis [129].
Thus, the exact contributions of each CK1 isoform in the various cell death pathways, and their underlying
regulatory mechanisms, are not well established, and more selective tools are required in order to ascertain
which CK1 isoform acts where in the distinct cell death pathways.
Contribution of CK1 to human pathologies
Given the involvement of CK1 isoforms in many, key signalling pathways involved in regulating proliferation,
cell growth and viability, both during development and in tissue homeostasis, it is unsurprising that dysfunc-
tional CK1 activity has been linked to many human diseases. Of note, neurodegeneration and cancer are par-
ticularly prominent diseases that CK1 isoforms have been implicated in [16,17,67,130]. In addition to the
obvious effects dysfunctional CK1 activity would have on p53-dependent genomic stability as discussed above,
CK1ɛ mutations in breast cancer were found to cause loss-of-function in the canonical Wnt signalling pathway
[131]. CK1ɛ expression was also found to be elevated in a variety of adenoid cystic carcinomas, including those
derived from ovarian, renal and prostatic cancers [132,133]. Additionally, CK1α was found to be essential for
acute myeloid leukemia (AML) viability, and treatment with the CK1 inhibitor D4476 resulted in selective
killing of the AML cells [91]. However, a common theme that has emerged whilst investigating the functions of
CK1 isoforms, is that they can act in both a positive and negative manner within the same signalling pathways.
This clearly points to multiple CK1 substrates whose phosphorylation is uniquely regulated, and thus, the
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 4613
Biochemical Journal (2020) 477 4603–4621
https://doi.org/10.1042/BCJ20200506
D
ow
nloaded from
 http://portlandpress.com
/biochem
j/article-pdf/477/23/4603/899593/bcj-2020-0506c.pdf by U
K user on 14 D
ecem
ber 2020
utility of CK1 inhibitors in different diseases will be highly dependent on both the specificity of the inhibitor,
and whether the antagonistic effects of CK1 isoforms within the same signalling pathways can be segregated
and targeted separately.
The role of CK1 isoforms in neurodegenerative diseases is perhaps best showcased in Alzheimer’s disease
(AD). CK1δ transcripts are up-regulated 30-fold in the hippocampus of AD brains [134], and it is thought that
CK1δ phosphorylates the AD-related protein tau, leading to the formation of neurofibrillary tangles [135].
Similarly, CK1ɛ has been proposed to regulate the processing of amyloid precursor protein (APP), and thus
dysfunctional CK1ɛ activity has been linked to the formation of amyloid plaques [136].
In some cases, the pathogenicity of dysfunctional CK1 signalling can be attributed to mutations occurring in
regulatory CK1 binding partners. This is perhaps best showcased in FAM83G. Recently, palmoplantar
keratoderma-associated mutations within FAM83G were shown to disrupt the interaction between FAM83G
and CK1α [64]. Both human cancer cells and Xenopus embryos harbouring these mutations, presented with
dysfunctional Wnt signalling [64], suggesting that loss of the CK1α spatiotemporal regulation imparted by
FAM83G may be a key event in the pathogenesis of the disease. Furthermore, mutations in FAM83H are asso-
ciated with the dental disease amelogenesis imperfecta (AI) [137–140]. FAM83H interacts and co-localises with
CK1α, δ and ɛ isoforms, on punctate cytoplasmic and nuclear speckles [56,139,141–143]. AI-associated
FAM83H mutations result in N-terminal truncations of the FAM83H protein, generating FAM83H species that
maintain CK1-binding, but lack the C-terminus, which presumably regulates FAM83H localisation [56,57].
These FAM83H mutant proteins localise to the nucleus and thereby re-direct CK1 activity to the nucleus in
the process. Whether this change in localisation is a driver of FAM83H-associated AI, or merely a
co-occurrence is yet to be determined, but it is tantalising to speculate that nuclear CK1, triggered by an AI
mutant of FAM83H re-directing CK1 to the nucleus, may result in dysfunctional CK1 signalling, and poten-
tially allow CK1 isoforms to access novel substrates which they would not usually encounter. Thus, the role of
CK1 isoforms in disease is complex, and can be attributed to many factors, including mutations within the
catalytic domain, as well as loss of spatiotemporal control resulting from mutations within regulatory subunits,
such as FAM83 proteins.
Inhibiting CK1 isoforms
Given such pleiotropy in the cellular roles of CK1 kinases, they have long been deemed undruggable enzymes.
Thus, methods to selectively inhibit CK1-specific functions, in a temporally and spatially controlled manner,
are highly warranted, yet extremely challenging to generate. That said, recent years have seen increasing interest
in CK1 isoforms as drug targets [67]. However, due to the high homology between their kinase domains,
isoform-specific CK1 inhibitors have been very difficult to develop, particularly in the case of CK1δ and ɛ
which share the highest degree of homology within the CK1 isoforms (Figure 1B) [17]. Nonetheless, several
small-molecule CK1 inhibitors have been generated and many have been used to aid research into CK1 func-
tion [17,67]. However, and importantly, due to their inhibition of the pan-cellular pool of CK1 isoforms, data
should be interpreted with caution, especially when assigning CK1-substrate relationships.
As alternative approaches to kinase inhibition, the thalidomide-related drug lenalidomide, of the immuno-
modulatory imide drug (iMiD) family, was recently found to induce the degradation of CK1α through recruit-
ing CK1α to the Cereblon-containing Cullin 4 ubiquitin E3 ligase complex, for its subsequent ubiquitination
and proteolytic degradation [144]. Such treatment with lenalidomide was shown to be effective in the treatment
of pre-leukemic human myelodysplastic syndrome (MDS). MDS patients present with a deletion of one allele
of the CSNK1A1 gene leading to haploinsufficiency of the CK1α protein [144]. Moreover, there are other
thalidomide-derivatives, including pomalidomide and BTX161, that have recently been reported to lead to the
degradation of CK1α [145,146]. In agreement with important regulatory roles for CK1-interacting proteins in
cells, the degradation of CK1α in response to iMiD treatment appears to be dependent on the nature of the
FAM83–CK1α complex [146]. Specifically, FAM83F is co-degraded with CK1α but other FAM83–CK1α com-
plexes appear to be spared from degradation [146]. Given most CK1 isoforms appear to be in complex with
specific FAM83 proteins, targeting specific FAM83–CK1 complexes may yet allow one to degrade and inhibit
context-specific CK1 activity. In addition to these iMiD-based targeting strategies, CK1α-derived peptides have
been successfully employed to block binding between CK1α and MDM2 [70]. These blocked the CK1α–
MDM2 interaction without inhibiting CK1α kinase activity, and led to a reduction in p53 proteolysis with con-
current heightened p53 stability [70]. Such approaches are attractive as they provide a means to inhibit selective
CK1-dependent processes, whilst rendering other, unrelated CK1-associated processes, as well as CK1 catalytic
© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).4614
Biochemical Journal (2020) 477 4603–4621
https://doi.org/10.1042/BCJ20200506
D
ow
nloaded from
 http://portlandpress.com
/biochem
j/article-pdf/477/23/4603/899593/bcj-2020-0506c.pdf by U
K user on 14 D
ecem
ber 2020
activity, intact. Although, one can imagine that such peptides would impact the binding to other
CK1-interacting proteins, and lenalidomide-induced proteolysis is known to target many other proteins other
than CK1α for proteasomal degradation [147].
Interestingly, targeted proteolysis of FAM83D through the Affinity-directed PROtein Missile (AdPROM)
system [148,149] was shown to disrupt CK1α localisation to mitotic spindles [58]. Thus, presumably, degrad-
ation of FAM83D disrupted the mitotic functions of CK1α without impacting the other, non-mitotic CK1α
processes. In a similar vein, ablation of FAM83G severely impeded canonical Wnt signalling through disruption
of the FAM83G–CK1α interaction [60], again presumably without affecting other, non-Wnt CK1α processes.
Thus, targeting the CK1-interacting regulatory proteins may prove to be a viable means of turning off a specific
CK1 process, independently from kinase inhibition and thereby bypassing the detrimental effects of pan-
cellular CK1 targeting.
Challenges encountered when studying CK1 isoforms
Despite such extensive research into CK1 biology over the last few decades, the study of CK1 isoforms within
their endogenous settings has proved difficult. Given such a high degree of homology within their kinase
domains, the generation of selective antibodies to enable immunofluorescence-based localisation and
immunoprecipitation-based interactome studies have proved challenging. This problem is particularly apparent
for CK1δ/ɛ, which have highly similar sequences even outside their kinase domains [67]. Thus, immunopreci-
pitation experiments often precipitate multiple CK1 isoforms, and localisation studies depict more than just the
intended CK1 isoform, making false-positive observations a common occurrence. In the case of immunoblot-
ting, the difference in molecular weight between CK1α and CK1δ/ɛ allows robust identification of CK1α by
SDS–PAGE. However, as CK1δ/ɛ display an almost identical electrophoretic mobility pattern, segregation of
these two CK1 isoforms is challenging. Another point to consider is the lack of selectivity amongst currently
available CK1 inhibitors, both between CK1 isoforms, and other members of the kinome [10]. Finally, even
when one is able to target a CK1 isoform specifically, as in the case of RNAi-based knockdown experiments,
the pan-cellular knockdown of CK1 affects all of the associated signalling processes, making it virtually impos-
sible to dissect individual effects of CK1 isoform removal within the context of a specific signalling event.
These specificity problems are further exacerbated by the existence of multiple splice variants for certain CK1
isoforms [16,21,67]. Thus, until tools are developed to overcome these challenges, phosphoproteomic studies
seeking to capture and define the substrate landscape for each CK1 isoform will be very hard to dissect, yet this
remains an important outstanding area to resolve.
However, recent advances in genome editing may overcome some of these limitations, and allow selective
and specific research into individual CK1 isoforms. Through knocking in epitope tags into individual CK1 loci,
the true subcellular distribution and changes in interactomes of individual CK1 isoforms upon modulation of
individual signalling pathways can be assessed, assuming the tags themselves do not interfere with CK1 biology
in the first place. Indeed, knockin of an mCherry tag into the CSNK1A1 and CSNK1E loci allowed robust
assessment of CK1α and ɛ localisation during mitosis [58]. More recently, knockin of VenusMAP onto
CSNK1D and CSNK1E identified a vesicle-localised CK1δ/ɛ substrate, GTPase-activating protein and VPS9
domain-containing protein 1 (GAPVD1), required for endocytosis [150]. Expansion of this approach will likely
see the identification of highly specific CK1 interaction partners, as well as enable detailed profiling of CK1
isoform localisation in response to cell cycle stage and different stimuli. In a similar vein, CRISPR/Cas9 gene
editing could be utilised to generate analog-sensitive CK1 isoforms in order to capture the specific substrates of
each CK1 member [151]. Such an approach would have the added benefit of rendering the modified analog-
sensitive CK1 isoforms sensitive to analog-sensitive kinase inhibitors, whilst the other wild-type isoforms
would not be targeted for inhibition [151]. Consequently, CK1 isoforms could in principle be inhibited very
selectively.
Conclusions and perspectives
Given the diverse range of CK1 functions within the cell, and their regulatory roles within many signalling
pathways, CK1 isoforms are key players in cell biology. However, and as discussed above, the seemingly contra-
dictory roles of CK1 isoforms within the same signalling pathways make CK1 isoforms exceptionally difficult
therapeutic targets. Future efforts aimed at researching CK1 functional binding partners, such as FAM83 pro-
teins, and proceeding to disrupt their interaction with the aim of selectively inhibiting a CK1-specific process,
may provide an attractive alternative means of targeting CK1 kinases, to facilitate basic research and develop
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potential therapeutic interventions. In order for such approaches to be successful, there is a drastic need to
improve the research design, data analysis and interpretation of findings in the field of CK1 research. Impeding
factors such as cross-reacting antibodies (either in immunofluorescence, immunoblotting or immunoprecipita-
tion approaches), and non-isoform selective inhibitors, can add confusion to an already complicated biological
problem. Through using CK1 isoform-specific antibodies and other reagents, correct kinase-substrate relation-
ships can be established, and one could quickly and confidently assay which CK1 kinase is participating in the
biological event in question. In cases where CK1 isoform-specific antibodies cannot be used reliably, CRISPR/
Cas9-based gene editing strategies, aimed at targeting the endogenous CK1 loci with epitope tags, will undoubt-
edly provide a means of assessing the true localisation profiles of these dynamic kinases. Once regarded as pro-
miscuous kinases, the emerging roles and regulation of these distinct CK1 isoforms has highlighted the
diversity of fundamental cellular functions that these enzymes co-ordinate. Armed with better tools, reagents
and novel strategies to modulate specific CK1 functions, accurate determination of the physiological substrates
for each CK1 member can be achieved.
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